- Home
- NAAS vs CHRO Comparison
NAAS vs CHRO Comparison
Compare NAAS & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- CHRO
- Stock Information
- Founded
- NAAS 2019
- CHRO 2002
- Country
- NAAS China
- CHRO United States
- Employees
- NAAS N/A
- CHRO N/A
- Industry
- NAAS Other Specialty Stores
- CHRO
- Sector
- NAAS Consumer Discretionary
- CHRO
- Exchange
- NAAS Nasdaq
- CHRO Nasdaq
- Market Cap
- NAAS 8.3M
- CHRO 8.1M
- IPO Year
- NAAS 2017
- CHRO 2024
- Fundamental
- Price
- NAAS $0.55
- CHRO $1.37
- Analyst Decision
- NAAS
- CHRO Strong Buy
- Analyst Count
- NAAS 0
- CHRO 1
- Target Price
- NAAS N/A
- CHRO N/A
- AVG Volume (30 Days)
- NAAS 258.9K
- CHRO 2.1M
- Earning Date
- NAAS 05-08-2025
- CHRO 05-14-2025
- Dividend Yield
- NAAS N/A
- CHRO N/A
- EPS Growth
- NAAS N/A
- CHRO N/A
- EPS
- NAAS N/A
- CHRO N/A
- Revenue
- NAAS $43,258,393.00
- CHRO N/A
- Revenue This Year
- NAAS $19.53
- CHRO N/A
- Revenue Next Year
- NAAS $151.36
- CHRO N/A
- P/E Ratio
- NAAS N/A
- CHRO N/A
- Revenue Growth
- NAAS 50.34
- CHRO N/A
- 52 Week Low
- NAAS $0.41
- CHRO $0.45
- 52 Week High
- NAAS $20.20
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- NAAS 39.74
- CHRO 46.67
- Support Level
- NAAS $0.41
- CHRO $1.29
- Resistance Level
- NAAS $0.50
- CHRO $1.65
- Average True Range (ATR)
- NAAS 0.07
- CHRO 0.20
- MACD
- NAAS 0.02
- CHRO 0.02
- Stochastic Oscillator
- NAAS 75.27
- CHRO 13.81
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.